CD274 and neoplasm: PD-L1 binds to PD-1 with a lower affinity compared to PD-L218, yet its widespread expression on tumor cells and significant association with clinical outcomes in different cancers, including HCC19,20, made it a better therapeutic target for immunotherapy.